While brown adipocyte-derived EVs have shown cardioprotective effects, treatment with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPARγ) activator used for type II diabetes, has revealed harmful effects. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.